This study used an optical technique to measure the effects of treating low (10 mg/kg) and high (25 mg/kg) doses of 3-iodothyronamine (T1AM) on the metabolism in the kidney and heart of mice. The ratio of two intrinsic fluorophores in tissue, (NADH/FAD), called the NADH redox ratio (NADH RR), is a marker of the metabolic state of the tissue. A cryofluorescence imaging instrument was used to provide a quantitative assessment of NADH RR in both kidneys and hearts in mice treated with 3-iodothyronamine. We compared those results to corresponding tissues in control mice. In the kidneys of mice treated with a high dose T1AM, the mean values of the maximum projection of NADH RR were 2.6 ± 0.6 compared to 3.20 ± 0.03 in control mice, indicating a 19% ( ± 0.4) significant increase in oxidative stress (OS) in the high dose-treated kidneys (P = 0.047). However, kidneys treated with a low dose of T1AM showed no difference in NADH RR compared to the kidneys of control mice. Furthermore, low versus high dose treatment of T1AM showed different responses in the heart than in the kidneys. The mean value of the maximum projection of NADH RR in the heart changed from 3.0 ± 0.3 to 3.2 ± 0.6 for the low dose and the high dose T1AM-treated mice, respectively, as compared to 2.8 ± 0.7 in control mice. These values correspond to a 9% (±0.5) (P = 0.045) and 14% (±0.5) (P = 0.008) significant increase in NADH RR in the T1AM-treated hearts, indicating that the high dose T1AM-treated tissues have reduced OS compared to the low dose-treated tissues or the control tissues. These results suggest that while T1AM at a high dose increases oxidative response in kidneys, it has a protective effect in the heart and may exert its effect through alternative pathways at different doses and at tissue specific levels.
ScanlanTSSuchlandKLHartMEChielliniGHuangYKruzichPJFrascarelliSCrossleyDABunzowJRRonca-TestoniSLinETHattonDZucchiRGrandyDK. 3-iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone. Nat Med2004; 10: 638–42.
2.
ChielliniGFrascarelliSGhelardoniSCarnicelliVTobiasSCDeBarberABrogioniSRonca-TestoniSCerbaiEGrandyDKScanlanTSZucchiR. Cardiac effects of 3-iodothyronamine: a new aminergic system modulating cardiac function. FASEB J2007; 21: 1597–608.
3.
ScanlanTS. Endogenous 3-Iodothyronamine (T(1)AM): more than we bargained for. J Clin Endocrin Metab2011; 96: 1674–6.
4.
BraulkeLJKlingensporMDeBarberATobiasSCGrandyDKScanlanTSHeldmaierG. 3-Iodothyronamine: a novel hormone controlling the balance between glucose and lipid utilisation. J Comp Physiol B2008; 178: 167–77.
5.
ManniMEDe SienaGSabaAMarchiniMLanducciEGeraceEZazzeriMMusilliCPellegrini-GiampietroDMatucciRZucchiRRaimondiL. Pharmacological effects of 3-iodothyronamine (T1AM) in mice include facilitation of memory acquisition and retention and reduction of pain threshold. Br J Pharmacol2013; 168: 354–62.
6.
KlieverikLPJanssenSFvan RielAFoppenEBisschopPHSerlieMJBoelenAAckermansMTSauerweinHPFliersEKalsbeekA. Thyroid hormone modulates glucose production via a sympathetic pathway from the hypothalamic paraventricular nucleus to the liver. Proc Natl Acad Sci USA2009; 106: 5966–71.
7.
GalliEMarchiniMSabaABertiSTonaccheraMVittiPScanlanTSIervasiGZucchiR. Detection of 3-iodothyronamine in human patients: a preliminary study. J Clin Endocrin Metab2012; 97: E69–E74.
8.
LodoviciMBigagliEBardiniGRotellaCM. Lipoperoxidation and antioxidant capacity in patients with poorly controlled type 2 diabetes. Toxicol Indus Health2009; 25: 337–41.
9.
RamanujamNRichards-KortumRThomsenSMahadevan-JansenAFollenMChanceB. Low temperature fluorescence imaging of freeze-trapped human cervical tissues. Opt Express2001; 8: 335–43.
10.
MalekiSSepehrRStaniszewskiKSheibaniNSorensonCMRanjiM. Mitochondrial redox studies of oxidative stress in kidneys from diabetic mice. Biomed Opt Express2012; 3: 273–81.
11.
RanjiMKanemotoSMatsubaraMGrossoMAGormanJH3rdGormanRCJaggardDLChanceB. Fluorescence spectroscopy and imaging of myocardial apoptosis. J Biomed Opt2006; 11: 064036–064036.
12.
RanjiMMatsubaraMLeshnowerBGHinmonRHJaggardDLChanceBGormanRCGorman IiiJH. Quantifying acute myocardial injury using ratiometric fluorometry. IEEE Trans Biomed Eng2009; 56: 1556–63.
13.
SepehrRStaniszewskiKMalekiSJacobsERAudiSRanjiM. Optical imaging of tissue mitochondrial redox state in intact rat lungs in two models of pulmonary oxidative stress. J Biomed Opt2012; 17: 046010–046010.
14.
ChanceBSchoenerBOshinoRItshakFNakaseY. Oxidation-reduction ratio studies of mitochondria in freeze-trapped samples. NADH and flavoprotein fluorescence signals. J Biol Chem1979; 254: 4764–71.
15.
RanjiMNiokaSXuHNWuBHLiLZJaggardDLChanceB. Fluorescent images of mitochondrial redox states in in situ mouse hypoxic ischemic intestines. J Innov Opt Health Sci2009; 2: 365–74.
16.
LewisKEChungRSWestAKChuahMI. Distribution of exogenous metallothionein following intraperitoneal and intramuscular injection of metallothionein-deficient mice. Histol Histopathol2012; 27: 1459–70.
17.
JiangCHWangXFYinBLiXYCuiXM. Effects of exogenous nitric oxide on the subcellular distribution and chemical forms of copper in tomato seedlings under copper stress. Ying Yong Sheng Tai Xue Bao2012; 23: 3033–9.
18.
ZhangZHBlessingtonDLiHBuschTMGlicksonJLuoQMChanceBZhengG. Redox ratio of mitochondria as an indicator for the response of photodynamic therapy. J Biomed Opt2004; 9: 772–8.
19.
XuHNZhaoHMirTALeeSCFengMChoeRGlicksonJDLiLZ. Chop therapy induced mitochondrial redox state alteration in non-Hodgkin's lymphoma xenografts. J Innov Opt Health Sci2013; 6: 1350011–1350011.
20.
OstranderJHMcMahonCMLemSMillonSRBrownJQSeewaldtVLRamanujamN. Optical redox ratio differentiates breast cancer cell lines based on estrogen receptor status. Cancer Res2010; 70: 4759–66.
21.
LiLZXuHNRanjiMNiokaSChanceB. Mitochondrial redox imaging for cancer diagnostic and therapeutic studies. J Innov Opt Health Sci2009; 2: 325–41.
22.
MalekiSSepehrRStaniszewskiKSheibaniNSorensonCMRanjiM. Mitochondrial redox studies of oxidative stress in kidneys from diabetic mice. Biomed Opt Express2012; 3: 273–81.
23.
RanjiMJaggardDLAprelevaSVVinogradovSAChanceB. Simultaneous fluorometry and phosphorometry of Langendorff perfused rat heart: ex vivo animal studies. Opt Lett2006; 31: 2995–7.
24.
MatsubaraMRanjiMLeshnowerBGNomaMRatcliffeSJChanceBGormanRCGormanJH3rd. In vivo fluorometric assessment of cyclosporine on mitochondrial function during myocardial ischemia and reperfusion. Ann Thorac Surg2010; 89: 1532–7.
25.
ChielliniGErbaPCarnicelliVManfrediCFrascarelliSGhelardoniSMarianiGZucchiR. Distribution of exogenous [125I]-3-iodothyronamine in mouse in vivo: relationship with trace amine-associated receptors. J Endocrinol2012; 213: 223–30.
26.
MalekiSGopalakrishnanSGhanianZSepehrRSchmittHEellsJRanjiM. Optical imaging of mitochondrial redox state in rodent model of retinitis pigmentosa. J Biomed Opt2013; 18: 16004–16004.
27.
GreenDREvanGI. A matter of life and death. Cancer Cell2002; 1: 19–30.
28.
TodaroMZeunerAStassiG. Role of apoptosis in autoimmunity. J Clin Immunol2004; 24: 1–11.
29.
FierabracciPPincheraAMartinelliSScartabelliGSalvettiGGiannettiMPucciAGalliGRiccoIQuerciGRagoTDi SalvoCAnselminoMVittiPSantiniF. Prevalence of endocrine diseases in morbidly obese patients scheduled for bariatric surgery: beyond diabetes. Obes Surg2011; 21: 54–60.
30.
SabaAChielliniGFrascarelliSMarchiniMGhelardoniSRaffaelliATonaccheraMVittiPScanlanTSZucchiR. Tissue distribution and cardiac metabolism of 3-iodothyronamine. Endocrinology2010; 151: 5063–73.
31.
HoefigCSKohrleJBrabantGDixitKYapBStrasburgerCJWuZ. Evidence for extrathyroidal formation of 3-iodothyronamine in humans as provided by a novel monoclonal antibody-based chemiluminescent serum immunoassay. J Clin Endocrin Metab2011; 96: 1864–72.
32.
FrascarelliSGhelardoniSChielliniGGalliERoncaFScanlanTSZucchiR. Cardioprotective effect of 3-iodothyronamine in perfused rat heart subjected to ischemia and reperfusion. Cardiovasc Drug Ther2011; 25: 307–13.
33.
WattINMontgomeryMGRunswickMJLeslieAGWWalkerJE. Bioenergetic cost of making an adenosine triphosphate molecule in animal mitochondria. Proc Natl Acad Sci USA2010; 107: 16823–7.
34.
CumeroSFogolariFDomenisRZucchiRMavelliIContessiS. Mitochondrial F0F1-ATP synthase is a molecular target of 3-iodothyronamine, an endogenous metabolite of thyroid hormone. Brit J Pharmacol2012; 166: 2331–47.
35.
GogliaFLanniAHorstCMorenoMThomaR. In vitro binding of 3,5-di-iodo-L-thyronine to rat liver mitochondria. J Mol Endocrinol1994; 13: 275–82.
36.
LanniAMorenoMCioffiMGogliaF. Effect of 3,3'-di-iodothyronine and 3,5-di-iodothyronine on rat liver mitochondria. J Endocrinol1993; 136: 59–64.
37.
VendittiPNapolitanoGDi StefanoLChielliniGZucchiRScanlanTSDi MeoS. Effects of the thyroid hormone derivatives 3-iodothyronamine and thyronamine on rat liver oxidative capacity. Mol Cell Endocrinol2011; 341: 55–62.
38.
ChanceBCohenPJobsisFSchoenerB. Intracellular oxidation-reduction states in vivo. Science1962; 137: 499–508.
39.
Avi-DorYOlsonJDohertyMKaplanN. Fluorescence of pyridine nucleotides in mitochondria. Biol Chem1962; 237: 7–7.
40.
KlaidmanLKLeungACAdamsJDJr. High-performance liquid chromatography analysis of oxidized and reduced pyridine dinucleotides in specific brain regions. Anal Biochem1995; 228: 312–7.
41.
HeikalAA. Intracellular coenzymes as natural biomarkers for metabolic activities and mitochondrial anomalies. Biomark Med2010; 4: 241–63.
42.
AldakkakMStoweDFLesnefskyEJHeisnerJSChenQCamaraAK. Modulation of mitochondrial bioenergetics in the isolated Guinea pig beating heart by potassium and lidocaine cardioplegia: implications for cardioprotection. J Cardiovasc Pharmacol2009; 54: 298–309.
